Has Steven Gershon, MD received payments from drug or device companies?

Yes. Drug and device makers reported $596,751 in general payments to Steven Gershon, MD across 598 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Steven Gershon, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Steven Gershon, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Steven Gershon, MD

Pain Medicine · Virginia Beach, VANPI 1073541736

Payments from drug & device makers

$596,751in general payments, 2019–2025

Across 598 payments — averaging $997.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Seikagaku Corporation$509K
AbbVie$36K
Kowa Pharmaceuticals America, Inc.$24K
Eli Lilly$10K
Vertex$9K
Nevro Corp.$825
plus $8K from 54 others

$111in research payments, 2019–2025

Across 1 payment — averaging $111.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$111

What the payments were for

Consulting fees$31,29040%
Speaking & faculty fees$32,43842%
Travel & lodging$1,5702%
Food & beverage$12,77216%
Education$70%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Seikagaku Corporation	49	$508,712
AbbVie(2 entities)	202	$35,671
Kowa Pharmaceuticals America, Inc.	19	$24,403
Eli Lilly	1	$9,962
Vertex	17	$9,383
Nevro Corp.	14	$825
Lundbeck LLC	24	$658
Pfizer	38	$613
Boston Scientific	6	$520
Medtronic(2 entities)	7	$415
Lilly USA, LLC	16	$344
Amgen(2 entities)	11	$324
Bioventus LLC	9	$310
Abbott	11	$293
Merz Pharmaceuticals, LLC	10	$280
Avanir Pharmaceuticals, Inc.	9	$250
Fidia Pharma USA Inc.	10	$232
Novartis	12	$226
Biohaven Pharmaceuticals, Inc.	6	$209
Si-bone, Inc.	5	$200
Stimwave Technologies Incorporated	3	$183
Ipsen Biopharmaceuticals, Inc	8	$169
Intrinsic Therapeutics	1	$168
Relievant Medsystems, Inc.	2	$156
Eisai Inc.	3	$153
Globus Medical	2	$133
Collegium Pharmaceutical, Inc.	6	$123
IBSA Pharma Inc.	5	$116
Medical Device Business Services, Inc.	1	$114
Teva Pharmaceuticals USA, Inc.	7	$113
Biodelivery Sciences International, Inc.	6	$100
Johnson & Johnson	3	$97
Merck	5	$90
SPR Therapeutics, Inc	4	$88
Scilex Pharmaceuticals Inc.	5	$85
Almatica Pharma LLC	5	$82
Arbor Pharmaceuticals, Inc.	5	$77
Electronic Waveform Lab, Inc.	5	$77
Currax Pharmaceuticals LLC	5	$76
Zyla Life Sciences, Inc.	5	$69
MDD US Operations, LLC	5	$69
Biohaven Pharmaceutical Holding Company Ltd.	4	$59
Assertio Therapeutics, Inc.	3	$48
Tonix Medicines, Inc.	2	$47
Azurity Pharmaceuticals, Inc.	2	$44
Impel Pharmaceuticals Inc.	2	$41
Kaleo, Inc.	2	$38
Avanos Medical	2	$36
Painteq LLC	1	$34
Hikma Pharmaceuticals USA	2	$32
Curonix LLC	1	$32
Biogen	1	$27
Ultragenyx Pharmaceutical Inc.	1	$18
Pacira Therapeutics, Inc.	1	$18
Ferring Pharmaceuticals Inc.	1	$17
GRT US Holding, Inc.	1	$17
Averitas Pharma Inc.	1	$16
AstraZeneca	1	$15
Baudax Bio Inc.	1	$15
Sanofi-aventis U.S. LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

UBRELVY$28,168
Seglentis$24,197
QULIPTA$21,038
JOURNAVX$8,121
BARRICAID ACD (ANNULAR CLOSURE DEVICE)$336
WaveWriter Alpha Prime 16$241
Omnia$169
Senza Spinal Cord Stimulation System$125
VYEPTI$125
Leqembi$121
AIMOVIG$118
Stimrouter Implantable Kit$118
NURTEC ODT$117
NUEDEXTA$115
VIPER$114
CONCORDE$114
CONDUIT$114
INTELLIS$111

How this compares

$596,751 in reported general payments places this provider in the 95th percentile of 150 pain medicine providers in Virginia.

See all pain medicine providers in Virginia →

Medicare billing

Part B allowed, 2024

$435,241

Medicare patients

826

Services billed

7,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	12	$292
Acetaminophen-CodeineAcetaminophen With Codeine	12	$199

Paid to pharmacies, not to this prescriber.

Other pain medicine in Virginia Beach

Victor TsengVirginia Beach$13K
Robert SpearVirginia Beach$4K
Michael DepalmaRichmond$967K
Lynn KohanCharlottesville$667K
Chheany UngRoanoke$624K
Denise LesterRichmond$459K
Nameer HaiderWoodbridge$143K
Daniel KendallMc Lean$100K
Jared DavisFishersville$45K
George BaylorSalem$24K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →